 specif low dose fadrozol hydrochlorid cg aromatas inhibitor cg fadrozol hydrochlorid potent cytochrom steroidogenesi inhibitor aromatas low dose biosynthet step concentr recent studi inhibit corticosteron methyloxidase-ii deoxycorticosteron convers agent concentr blockad aromatas phase studi select inhibit aromatas possibl low dose cg phase II studi postmenopaus women metastat breast cancer effect low dose cg estrogen mineralocorticoid glucocorticoid secret dose schedul dose level prior dose escal protocol studi plasma estron estradiol sulfat urinari estron estradiol mg cg twice daili time dose schedul isotop kinet studi decreas rate convers androstenedion patient mg cg regimen basal level aldosteron cortisol period observ clinic examin plasma electrolyt urinari sodium/potassium ratio biolog evid mineralo-corticoid defici acth-stimul cortisol concentr dose level valu peak respons nmol/l basal differ nmol/l instanc reflect inhibit basal acth-stimul level respons cg androstenedion alpha-hydroxyprogesteron upward trend respons drug treatment acth-stimul aldosteron level extent cortisol reflect corticosteron methyloxidas type II blockad result cg dose mg daili block import inhibit cortisol aldosteron biosynthesi agent glucocorticoid mineralocorticoid supplement